AstraZeneca (AZN) Tops Q1 EPS by $1.06

AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $1.89, $1.06 better than the analyst estimate of $0.83. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $10.99 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
• Home Federal Bancorp of Louisiana (HFBL) Tops Q2 EPS by 46c
• Short sellers pile into SpaceX ahead of earnings, lockup expiration